Lehrstuhl für Innere Medizin I (Medizin 1)

Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients (2018) Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, et al. Conference contribution Alpha 4 beta 7 Integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages (2018) Schleier L, Wiendl M, Binder MT, Atreya R, Watson A, Neufert C, Atreya I, et al. Conference contribution The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis (2018) Schmitt H, Billmeier U, Ulmschneider J, Admyre C, Knittel T, Zargari A, Neurath M, Atreya R Conference contribution Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study (2018) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome (2018) Dillon J, Kulke M, Warner R, Bergsland E, Welin S, O'Dorisio T, Mckee C, et al. Conference contribution Whole-Body Electromyostimulation Combined With Individualized Nutritional Support Improves Body Composition in Patients With Hematological Malignancies - A Pilot Study (2018) Schink K, Relijic D, Herrmann HJ, Meyer J, Mackensen A, Neurath M, Zopf Y Journal article Medication safety in patients treated with new oral antitumor agents: A prospective, randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety, patient knowledge and patient well-being (AMBORA). Supported by the German Cancer Aid within the Comprehensive Cancer Center Erlangen-EMN (2018) Schlichtig K, Lechner P, Grafe C, Ferstl B, Fuchs F, Hein A, Meidenbauer N, et al. Conference contribution IBD IN 2017 Development of therapy for and prediction of IBD - getting personal (2018) Atreya R, Siegmund B Journal article Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study (2018) Pavel ME, Denecke T, Lahner H, Hoersch D, Rinke A, Koch A, Liyanage N, et al. Conference contribution